Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansion.
Animals
CD8-Positive T-Lymphocytes
/ immunology
Humans
Interleukin-1beta
/ genetics
Melanoma, Experimental
/ genetics
Mice
Mice, Knockout
Myeloid-Derived Suppressor Cells
/ immunology
NLR Family, Pyrin Domain-Containing 3 Protein
/ genetics
Neoplasm Proteins
/ genetics
Signal Transduction
/ genetics
T-Lymphocytes, Regulatory
/ immunology
IL-1
MDSCs
NLRP3
immunosuppression
Journal
Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876
Informations de publication
Date de publication:
09 03 2021
09 03 2021
Historique:
entrez:
2
3
2021
pubmed:
3
3
2021
medline:
17
8
2021
Statut:
ppublish
Résumé
Interleukin-1β (IL-1β)-mediated inflammation suppresses antitumor immunity, leading to the generation of a tumor-permissive environment, tumor growth, and progression. Here, we demonstrate that nucleotide-binding domain, leucine-rich containing family, pyrin domain-containing-3 (NLRP3) inflammasome activation in melanoma is linked to IL-1β production, inflammation, and immunosuppression. Analysis of cancer genome datasets (TCGA and GTEx) revealed greater NLRP3 and IL-1β expression in cutaneous melanoma samples (
Identifiants
pubmed: 33649199
pii: 2000915118
doi: 10.1073/pnas.2000915118
pmc: PMC7958415
pii:
doi:
Substances chimiques
IL1B protein, human
0
IL1B protein, mouse
0
Interleukin-1beta
0
NLR Family, Pyrin Domain-Containing 3 Protein
0
NLRP3 protein, human
0
Neoplasm Proteins
0
Nlrp3 protein, mouse
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIAID NIH HHS
ID : R01 AI015614
Pays : United States
Organisme : BLRD VA
ID : I01 BX001228
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK119394
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA197919
Pays : United States
Organisme : NIAID NIH HHS
ID : R56 AI015614
Pays : United States
Informations de copyright
Copyright © 2021 the Author(s). Published by PNAS.
Déclaration de conflit d'intérêts
Competing interest statement: L.A.B.J. serves on Olatec’s Scientific Advisory Board and receives compensation. C.A.D. serves as Chairman of Olatec’s Scientific Advisory Board, is co-Chief Scientific Officer, receives compensation, and has equity in Olatec. C.M. serves as Director for Olatec’s Innovative Science Program and has equity in Olatec.
Références
Lancet Oncol. 2012 Jan;13(1):e32-42
pubmed: 22225723
J Cardiovasc Pharmacol. 2019 Oct;74(4):285-296
pubmed: 31335445
Sci Rep. 2016 Oct 27;6:36107
pubmed: 27786298
J Biol Chem. 1996 Jul 12;271(28):16591-6
pubmed: 8663179
Arthritis Res Ther. 2018 Aug 3;20(1):169
pubmed: 30075804
Cancer Med. 2014 Aug;3(4):737-46
pubmed: 24692240
J Exp Med. 2010 May 10;207(5):1045-56
pubmed: 20385749
Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2645-50
pubmed: 12598651
J Immunother Cancer. 2018 May 9;6(1):32
pubmed: 29743104
Sci Rep. 2019 Aug 22;9(1):12277
pubmed: 31439870
J Clin Invest. 2020 May 1;130(5):2570-2586
pubmed: 32017708
Oncotarget. 2017 Mar 28;8(13):21539-21553
pubmed: 28423487
Blood. 1990 Mar 15;75(6):1305-10
pubmed: 2310829
Cancer Immunol Immunother. 2013 Nov;62(11):1711-22
pubmed: 24072401
Cell. 2017 Nov 2;171(4):934-949.e16
pubmed: 29033130
J Biol Chem. 2010 Feb 26;285(9):6477-88
pubmed: 20038581
Clin Cancer Res. 2016 Dec 1;22(23):5661-5672
pubmed: 27178742
Trends Immunol. 2016 Jun;37(6):364-374
pubmed: 27151281
Cancers (Basel). 2020 Jul 17;12(7):
pubmed: 32708981
Cancer Metastasis Rev. 2006 Sep;25(3):387-408
pubmed: 17043764
Proc Natl Acad Sci U S A. 2007 May 8;104(19):8041-6
pubmed: 17483456
Nat Med. 2009 Oct;15(10):1170-8
pubmed: 19767732
Oncotarget. 2017 Jan 10;8(2):3649-3665
pubmed: 27690299
Cancer Res. 2012 Nov 15;72(22):5721-32
pubmed: 22986739
J Clin Invest. 2015 Sep;125(9):3347-55
pubmed: 26325032
Cancer Immunol Res. 2016 Apr;4(4):345-53
pubmed: 26873574
Cancer Res. 2017 Nov 15;77(22):6429-6441
pubmed: 28951462
Leukemia. 2019 Aug;33(8):2034-2046
pubmed: 30737486
Nat Genet. 2001 Nov;29(3):301-5
pubmed: 11687797
Immunity. 2015 Oct 20;43(4):751-63
pubmed: 26384545
Lancet. 2001 Feb 17;357(9255):539-45
pubmed: 11229684
N Engl J Med. 2017 Sep 21;377(12):1119-1131
pubmed: 28845751
J Immunol. 1987 Jul 15;139(2):464-8
pubmed: 3298430
Front Immunol. 2018 Jun 11;9:1310
pubmed: 29942309
Nat Rev Immunol. 2019 Aug;19(8):477-489
pubmed: 31036962
Front Oncol. 2019 Nov 08;9:1223
pubmed: 31781510
JCI Insight. 2018 Dec 20;3(24):
pubmed: 30568030
Eur J Immunol. 2010 Dec;40(12):3347-57
pubmed: 21110318
J Immunol. 2009 Apr 15;182(8):4499-506
pubmed: 19342621
Blood. 2011 Apr 7;117(14):3720-32
pubmed: 21304099
Pigment Cell Melanoma Res. 2009 Jun;22(3):257-67
pubmed: 19368690
Pigment Cell Melanoma Res. 2012 Jul;25(4):506-13
pubmed: 22524199
Clin Cancer Res. 2016 Jun 15;22(12):2908-18
pubmed: 26787752
Vaccines (Basel). 2016 Nov 03;4(4):
pubmed: 27827871
Adv Exp Med Biol. 2014;816:437-69
pubmed: 24818733
Proc Natl Acad Sci U S A. 2019 Jan 22;116(4):1361-1369
pubmed: 30545915
Immunol Lett. 2017 Dec;192:1-6
pubmed: 28987474
Nat Rev Immunol. 2013 Jun;13(6):397-411
pubmed: 23702978
Proc Natl Acad Sci U S A. 2018 Feb 13;115(7):E1530-E1539
pubmed: 29378952
Leukemia. 2020 Mar;34(3):932-937
pubmed: 31586150
Lancet. 2017 Oct 21;390(10105):1833-1842
pubmed: 28855077
Cancer Metastasis Rev. 2010 Jun;29(2):317-29
pubmed: 20422276